Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?

Key Takeaways CRMD's DefenCath is an FDA-approved catheter lock solution reducing CRBSIs in chronic hemodialysis patients.CRMD saw higher-than-expected outpatient dialysis utilization of DefenCath, likely lifting Q4 revenues.DefenCath's unique FDA-approved status and patent protection through 2033 support top-line growth.CorMedix’s (CRMD) lead product, DefenCath (taurolidine plus heparin), is the company’s primary source of revenues. DefenCath was approved in 2023 as the first and only antimicrobial cathete ...